Literature DB >> 33806694

Understanding the Pathophysiology of Thrombotic APS through Animal Models.

Alex A Gandhi1, Shanea K Estes1, Christine E Rysenga1, Jason S Knight1.   

Abstract

Antiphospholipid syndrome (APS) is a leading acquired cause of thrombotic events, with a notable tendency to promote thrombosis in vascular beds of all sizes, including both arterial and venous circuits. While pathogenic antiphospholipid antibodies circulate at relatively stable levels in blood, thrombosis tends to manifest as discrete and acute events, suggesting the requirement for a "second hit." While this two-hit model is generally accepted, much remains to be learned about exactly how antiphospholipid antibodies predispose to thrombosis in vivo and exactly how this predisposition interacts with the second hit. To this end, investigators have turned to animal models. Numerous approaches for modeling APS in animals have been described to date, each with potential advantages and disadvantages. This review will attempt to describe the most common APS models employed so far while discussing some pros and cons of each. Mechanisms of thrombotic APS that have thus far been explored in animal models will also be briefly addressed.

Entities:  

Keywords:  animal models; antiphospholipid antibodies; antiphospholipid syndrome; thrombosis

Mesh:

Substances:

Year:  2021        PMID: 33806694      PMCID: PMC7961365          DOI: 10.3390/ijms22052588

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  62 in total

1.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

Review 2.  Antiphospholipid syndrome.

Authors:  Ricard Cervera
Journal:  Thromb Res       Date:  2017-03       Impact factor: 3.944

Review 3.  Critical review of mouse models of venous thrombosis.

Authors:  Jose A Diaz; Andrea T Obi; Daniel D Myers; Shirley K Wrobleski; Peter K Henke; Nigel Mackman; Thomas W Wakefield
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03       Impact factor: 8.311

4.  A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies.

Authors:  Kristi L Allen; Fabio V Fonseca; Venkaiah Betapudi; Belinda Willard; Jainwei Zhang; Keith R McCrae
Journal:  Blood       Date:  2011-11-21       Impact factor: 22.113

5.  Cofactor-independent human antiphospholipid antibodies induce venous thrombosis in mice.

Authors:  D Manukyan; N Müller-Calleja; S Jäckel; K Luchmann; R Mönnikes; K Kiouptsi; C Reinhardt; K Jurk; U Walter; K J Lackner
Journal:  J Thromb Haemost       Date:  2016-03-16       Impact factor: 5.824

6.  Rose Bengal Photothrombosis by Confocal Optical Imaging In Vivo: A Model of Single Vessel Stroke.

Authors:  Lora Talley Watts; Wei Zheng; R Justin Garling; Victoria C Frohlich; James Donald Lechleiter
Journal:  J Vis Exp       Date:  2015-06-23       Impact factor: 1.355

7.  Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo.

Authors:  Christophe Dubois; Laurence Panicot-Dubois; Glenn Merrill-Skoloff; Bruce Furie; Barbara C Furie
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

8.  The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study.

Authors:  B de Laat; V Pengo; I Pabinger; J Musial; A E Voskuyl; I E M Bultink; A Ruffatti; B Rozman; T Kveder; P de Moerloose; F Boehlen; J Rand; Z Ulcova-Gallova; K Mertens; P G de Groot
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

9.  Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS.

Authors:  Valerie Proulle; Richard A Furie; Glenn Merrill-Skoloff; Barbara C Furie; Bruce Furie
Journal:  Blood       Date:  2014-05-13       Impact factor: 22.113

10.  Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'.

Authors:  Bianca C H Lutters; Ronald H W M Derksen; Winnie L Tekelenburg; Peter J Lenting; Jef Arnout; Philip G de Groot
Journal:  J Biol Chem       Date:  2003-06-13       Impact factor: 5.157

View more
  2 in total

1.  Differences in Endothelial Activation and Dysfunction Induced by Antiphospholipid Antibodies Among Groups of Patients With Thrombotic, Refractory, and Non-refractory Antiphospholipid Syndrome.

Authors:  Manuela Velásquez; Luisa F Peláez; Mauricio Rojas; Raúl Narváez-Sánchez; Jesús A Velásquez; Carlos Escudero; Sebastián San Martín; Ángela P Cadavid
Journal:  Front Physiol       Date:  2021-12-02       Impact factor: 4.566

2.  Inhibition of platelet-derived growth factor pathway suppresses tubulointerstitial injury in renal congestion.

Authors:  Takuma Matsuki; Takuo Hirose; Yusuke Ohsaki; Satoshi Shimada; Akari Endo; Hiroki Ito; Chika Takahashi; Seiko Yamakoshi; Ikuko Oba-Yabana; Go Anan; Toshiko Kato; Ryo Tajima; Shingo Nakayama; Tomoyoshi Kimura; Hannah Nakamura; Junichi Tani; Kazuhiro Takahashi; Shigeo Kure; Takefumi Mori
Journal:  J Hypertens       Date:  2022-08-19       Impact factor: 4.776

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.